This article is a correction to:
High expression level of the FTH1 gene is associated with poor prognosis in children with non-M3 acute myeloid leukemia
Junlin Zhang1
Liying Liu1Jinshuang Wei1
Xiaojing Wu1Jianming Luo1,2Hongying Wei1Liao Ning1,2*
Yunyan He1,2*- 1First Affiliated Hospital of Guangxi Medical University, Nanning, China
- 2The Key Laboratory of Children’s Disease Research in Guangxi’s Colleges and Universities, Education Department of Guangxi Zhuang Autonomous Region, Nanning, China
A corrigendum on
High expression level of the FTH1 gene is associated with poor prognosis in children with non-M3 acute myeloid leukemia
by Zhang J, Liu L, Wei J, Wu X, Luo J, Wei H, Ning L and He Y (2023). Front. Oncol. 12:1068094. doi: 10.3389/fonc.2022.1068094
In the published article, there was an error in affiliations 1,2,3. Instead of “1. First Affiliated Hospital of Guangxi Medical University, Nanning, China, 2. The Key Laboratory of Children’s Disease Research in Guangxi’s Colleges and Universities, Education Department of Guangxi Zhuang Autonomous Region, Nanning, China, 3. The Affiliated Children’s Hospital of Suzhou University, Suzhou, Jiangsu, China” it should be “1. First Affiliated Hospital of Guangxi Medical University, Nanning, China, 2. The Key Laboratory of Children’s Disease Research in Guangxi’s Colleges and Universities, Education Department of Guangxi Zhuang Autonomous Region, Nanning, China".
In the published article, there was an error in the legend for Figure 6 as published. Figure 6B is missing statement describing PCR results. The corrected legend appears below.
FIGURE 6
Figure 6 (A) RCC2: (P=0.021), Hazard Ratio (HR)=1.542; ABHD17B: (P=0.010), R=1.406. FTH1: (P=0.043), HR=0.786; IRAK1: (P=0.020), HR=1.504. (B) QRT-PCR validation of RCC2, ABHD17B, FTH1 and IRAK1 expression, Normal versus AML (P=0.020, P < 0.0001, P=0.013, P=0.031). (C) Survival analysis of FTH1 in hospital samples (purple represents that the gene is up in the sample and green represents that the gene is lowly expressed in the sample). (D) FTH1: 1-year AUC area of 0.953 and 2-year AUC area under the curve of 1.
(A) RCC2: (P=0.021), Hazard Ratio (HR)=1.542; ABHD17B: (P=0.010), R=1.406. FTH1: (P=0.043), HR=0.786; IRAK1: (P=0.020), HR=1.504. (B) QRT-PCR validation of RCC2, ABHD17B, FTH1 and IRAK1 expression, Normal versus AML (P=0.020, P < 0.0001, P=0.013, P=0.031). (C) Survival analysis of FTH1 in hospital samples (purple represents that the gene is up in the sample and green represents that the gene is lowly expressed in the sample). (D) FTH1: 1-year AUC area of 0.953 and 2-year AUC area under the curve of 1.
In the published article, there was an error in
Table 3 as published. Reverse primer format for ABHD17B is incorrect. The corrected Table 3 appears below.
TABLE 3
Table 3 The primers for selected genes.
In the published article, there was an error. Figure 6B lacks reference and description in the legend.
A correction has been made to “3 Result”, “3.4 Identification of biomarkers that predict poor prognosis in risk groups”, paragraph 1. This sentence previously stated:
“Results of one-way Cox analysis in the TCGA database showed that four genes, RCC2, ABHD17B, FTH1, IRAK1, were associated with AML prognosis (Figure 6A). In the 27 hospital samples, patients were divided —as per median expression levels of the four candidate genes— into high and low expression groups. After survival analysis, FTH1 was identified as a key gene for AML prognosis (Figure 6B). The specificity and sensitivity ROC were analyzed and the area under the curve (AUC) of the FTH1 survival curve was calculated (Figure 6C).”
The corrected sentence appears below:
“Results of one-way Cox analysis in the TCGA database showed that four genes, RCC2, ABHD17B, FTH1, IRAK1, were associated with AML prognosis (Figure 6A). Compared with the normal group, the expression levels of RCC2, ABHD17B, FTH1 and IRAK1 were up-regulated in the AML group (Figure 6B). In the 27 hospital samples, patients were divided —as per median expression levels of the four candidate genes— into high and low expression groups. After survival analysis, FTH1 was identified as a key gene for AML prognosis (Figure 6C). The specificity and sensitivity ROC were analyzed and the area under the curve (AUC) of the FTH1 survival curve was calculated (Figure 6D).”
The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: AML, WGCNA, FTH1, ferroptosis, prognosis
Citation: Zhang J, Liu L, Wei J, Wu X, Luo J, Wei H, Ning L and He Y (2023) Corrigendum: High expression level of the FTH1 gene is associated with poor prognosis in children with non-M3 acute myeloid leukemia. Front. Oncol. 13:1212991. doi: 10.3389/fonc.2023.1212991
Received: 27 April 2023; Accepted: 12 July 2023;
Published: 21 August 2023.
Edited and Reviewed by:
Jacopo Nanni, University of Bologna, ItalyCopyright © 2023 Zhang, Liu, Wei, Wu, Luo, Wei, Ning and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yunyan He, yunyanhe@aliyun.com; Liao Ning, ln12808@163.com